



(12) Translation of
European patent specification

(11) NO/EP 2523731 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/4188 (2006.01)
A61K 31/55 (2006.01)
A61P 5/00 (2006.01)
C07D 487/04 (2006.01)
C07F 9/6506 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.03.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.10.24
(86)	European Application Nr.	11702096.6
(86)	European Filing Date	2011.01.13
(87)	The European Application's Publication Date	2012.11.21
(30)	Priority	2010.01.14, US, 294980 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Novartis AG, Lichtstrasse 35, 4056 Basel, Sveits
(72)	Inventor	HU, Qi-Ying, Novartis Institutes for BioMedical Research, Inc.,100 Technology Square, Cambridge, Massachusetts 02139, USA KSANDER, Gary, 37 The Flume, Amherst, New Hampshire 03031, USA MEREDITH, Erik, Novartis Institutes for BioMedical Research, Inc.,100 Technology Square, Cambridge, Massachusetts 02139, USA MONOVICH, Lauren G., Novartis Institutes for BioMedical Research, Inc.,100 Technology Square, Cambridge, Massachusetts 02139, USA PAPILLON, Julien, Novartis Institutes for BioMedical Research, Inc.,100 Technology Square, Cambridge, Massachusetts 02139, USA SCHUMACHER, Christoph, Novartis Pharma AGPostfach, CH-4002 Basel, Sveits
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge


(54) Title **USE OF AN ADRENAL HORMONE-MODIFYING AGENT**

(56) References
Cited: EP-A1- 2 095 819, ULLA ENBERG ET AL: "New Aspects on Primary Aldosteronism", NEUROCHEMICAL
RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 28, no. 2, 1 February
2003 (2003-02-01), pages 327-332, XP019289614, ISSN: 1573-6903, WO-A1-2007/024945, WO-A2-
2007/139992

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluor-benzonitril med formel



5

eller et farmasøytisk akseptabelt salt derav, for anvendelse ved behandling av Cushings syndrom eller Cushings sykdom.

2. Forbindelsen eller det farmasøytisk akseptable saltet derav for anvendelse ifølge krav 1, hvori sykdommen eller forstyrrelsen er Cushings syndrom.


3. Forbindelsen eller det farmasøytisk akseptable saltet derav for anvendelse ifølge krav 1, hvori sykdommen eller forstyrrelsen er Cushings syndrom.

4. Forbindelsen eller det farmasøytisk akseptable saltet derav for anvendelse ifølge krav 1 eller 2, hvori Cushings syndrom inkluderer hyperkortisolisme som følge av adrenokortikale, hypofysiske eller ektopiske tumorer.

5. Forbindelsen for anvendelse ifølge krav 1 i form av dets dihydrogenfosfatsalt.

20

6. Forbindelse 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluor-benzonitril med formel



eller et farmasøytisk akseptabelt salt derav, for anvendelse ved behandling av hyperkortisolemi.

25

7. Forbindelsen for anvendelse ifølge krav 6 i form av dets dihydrogenfosfatsalt.

8. 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluor-benzonitrildihydrogenfosfat.